AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), announced the presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, held December...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO–Triumvira Immunologics Inc. (Triumvira), announced the upcoming presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, December 1-4, 2018, in San...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the University of...
TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on...
Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more...
Innovative immuno-therapy company welcomes former President and COO of Celgene AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to...
